Pfizer/Novo Battle Escalates; Lilly Registers Another ORC Study; New Lilly Orfor Manufacturing Site; GSK Ph3 MASH Program
A series of cardiometabolic-related news items have been observed from Pfizer/Metsera, Lilly, and GSK. Below, FENIX provides highlights and insights for the respective news items.
